Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(12):967-969; doi:10.1093/jnci/92.12.967
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 12, 967-969, June 21, 2000
© 2000 Oxford University Press

NEWS

Tyrosine Kinase Inhibitor Research Presses on Despite Halted Clinical Trial

Ken Garber

Successful drugs make headlines, but the failures quietly disappear from view. One experimental drug highly touted at previous American Association for Cancer Research meetings, Sugen Inc.’s SU-101, was notably absent from this year’s poster sessions. But in hallways and hotel rooms, news of the drug’s fate quickly spread by word of mouth: the South San Francisco-based biotech company had terminated the phase III clinical trial. Another cancer drug had failed.

The news was especially disturbing, since SU-101 was in the vanguard of a class of drugs known as tyrosine kinase inhibitors. These agents have captivated oncologists because they are precisely targeted at cancer abnormalities and should be relatively nontoxic. And drug companies have embraced them with unprecedented eagerness: at least 18 tyrosine kinase inhibitors are in the clinic . . . [Full Text of this Article]

Enzymes and Oncogenes

Quick Metabolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
Q. Zhang, S. M. Thomas, V. W. Y. Lui, S. Xi, J. M. Siegfried, H. Fan, T. E. Smithgall, G. B. Mills, and J. R. Grandis
Phosphorylation of TNF-{alpha} converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation
PNAS, May 2, 2006; 103(18): 6901 - 6906.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Zhang, S. M. Thomas, S. Xi, T. E. Smithgall, J. M. Siegfried, J. Kamens, W. E. Gooding, and J. R. Grandis
Src Family Kinases Mediate Epidermal Growth Factor Receptor Ligand Cleavage, Proliferation, and Invasion of Head and Neck Cancer Cells
Cancer Res., September 1, 2004; 64(17): 6166 - 6173.
[Abstract] [Full Text] [PDF]